Progressive and Prognosis Role of Lipogenic Pathway in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis | ||
| The Medical Journal of Cairo University | ||
| Article 35, Volume 87, March, March 2019, Pages 249-256 PDF (686.38 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/mjcu.2019.52347 | ||
| Authors | ||
| REHAB M. SAMAKA, M.D.; MOHAMMAD I. SHABAN, M.D.; MERVAT M. SULTAN, M.D.; SHEREEN F. EL-GODAY, M.D.; DINA M. SWEED, M.Sc. | ||
| The Department of Pathology, Faculty of Medicine* and National Liver Institute**, Menoufia University, Shebin El-Kom, Egypt | ||
| Abstract | ||
| Abstract Background and Aims: Despite the advance in treatment modalities, Hepatocellular Carcinoma (HCC) remains a com-mon cause of cancer morbidity and mortality worldwide. Lipogenic pathway is expected to become a potential thera-peutic target for prevention and treatment of HCC. Aim of Study: Studying the role of lipogenic pathway in hepatocellular carcinoma. Material and Methods: We searched the PubMed and Google scholar databases for relevant studies that evaluated the expression of lipogenic pathway markers; Sterol Regulatory Element-binding Protein1 (SREBP1), Fatty Acid Synthase (FASN) and Stearoyl-CoA Desaturase1 (SCD1) in human HCC tissues. Results: This review included 12 studies that enrolled 1031 patients with HCC or chronic hepatitis and normal subjects. SREBP1, FASN and SCD1 were overexpressed in HCC. SREBP1 expression was positively correlated with FASN and SCD expressions (r=0.74, pConclusion: We concluded that lipogenic pathway acti-vation plays an important role in HCC development and prognosis. This review was registered with PROSPERO (CRD 42018087933). | ||
| Keywords | ||
| FASN; HCC; Lipogenic pathway; SCD1; SREBP1 | ||
|
Statistics Article View: 162 PDF Download: 227 |
||
